NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$19.36

+0.63 (+3.36%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $18.70
▼
$20.29
50-Day Range: $16.32
▼
$26.37
52-Week Range: $16.02
▼
$37.63

Volume: 366,564 shs
Average Volume: 559,006 shs
Market Capitalization: $379.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.25

Albireo Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 175.1% Upside
$53.25 Price Target
Short Interest: Bearish
11.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.57
Upright™ Environmental Score
News Sentiment: 0.93
Based on 5 Articles This Week
Insider Trading: Selling Shares
$48,983 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($7.95) to ($6.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

541st out of 1,095 stocks

Pharmaceutical Preparations Industry

256th out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
Albireo Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $53.25, Albireo Pharma has a forecasted upside of 175.1% from its current price of $19.36.
Amount of Analyst Coverage
Albireo Pharma has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.48% of the float of Albireo Pharma has been sold short.
Short Interest Ratio / Days to Cover
Albireo Pharma has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Albireo Pharma has recently increased by 4.48%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Albireo Pharma does not currently pay a dividend.
Dividend Growth
Albireo Pharma does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Albireo Pharma has received a 59.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Liver-disease medication (A05)", and "Constipation medication (A06)" products. See details.
Environmental Sustainability
The Environmental Impact score for Albireo Pharma is -1.57.

2.2

News and Social Media Coverage

News Sentiment
Albireo Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Albireo Pharma this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for ALBO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Albireo Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,983.00 in company stock.
Percentage Held by Insiders
Only 6.90% of the stock of Albireo Pharma is held by insiders.
Percentage Held by Institutions
91.34% of the stock of Albireo Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Albireo Pharma are expected to grow in the coming year, from ($7.95) to ($6.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Albireo Pharma is -10.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Albireo Pharma is -10.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Albireo Pharma has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

September 26, 2022 | americanbankingnews.com

Robert W. Baird Raises Albireo Pharma (NASDAQ:ALBO) Price Target to $43.00

September 24, 2022 | fool.com

Albireo Pharma, Inc. (NASDAQ: ALBO)

September 22, 2022 | marketwatch.com

Albireo Pharma Shares Rise After Royalty Agreement

September 22, 2022 | finance.yahoo.com

Albireo Announces $115 Million Royalty Monetization Agreement with Sagard

September 20, 2022 | finance.yahoo.com

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

September 8, 2022 | msn.com

Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

September 7, 2022 | finanznachrichten.de

Albireo Pharma, Inc.: Italian Medicines Agency Approves Reimbursed Access to Bylvay (odevixibat) For Patients with All PFIC Types

September 6, 2022 | finance.yahoo.com

Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patients with All PFIC Types

August 30, 2022 | nasdaq.com

Albireo Pharma To Announce ALGS Trial Data This Fall

August 25, 2022 | nasdaq.com

Albireo Pharma, Inc. (NASDAQ:ALBO) Analysts Are Reducing Their Forecasts For This Year

August 16, 2022 | benzinga.com

Recap: Albireo Pharma Q2 Earnings

August 16, 2022 | seekingalpha.com

Albireo Pharma stock slips ~26% after co cuts FY sales guidance for lead drug Bylvay

August 16, 2022 | finance.yahoo.com

Albireo Reports Q2 2022 Financial Results and Business Update

August 12, 2022 | finance.yahoo.com

Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt

August 11, 2022 | finance.yahoo.com

Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?

August 10, 2022 | finance.yahoo.com

Albireo Appoints New Members to Board of Directors

August 3, 2022 | finance.yahoo.com

Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

August 1, 2022 | finance.yahoo.com

Albireo to Report Q2 2022 Financial Results on August 15, 2022

July 25, 2022 | finance.yahoo.com

Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

July 6, 2022 | finance.yahoo.com

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

June 30, 2022 | finance.yahoo.com

Albireo to Present at the William Blair Biotech Focus Conference 2022

June 28, 2022 | finance.yahoo.com

Albireo Pharma, Inc. (NASDAQ:ALBO): When Will It Breakeven?

June 23, 2022 | finance.yahoo.com

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

June 8, 2022 | finance.yahoo.com

Albireo to Present New Data at the EASL International Liver Congress™ 2022

June 7, 2022 | finance.yahoo.com

Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings: 8/15/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALBO
CUSIP: N/A
CIK: 1322505
Web: www.albireopharma.com
Phone: (857) 254-5555
Fax: 203-796-5001
Employees: 130
Year Founded: 2003

Price Target and Rating

Average Stock Price Forecast: $53.25
High Stock Price Forecast: $61.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +175.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,030,000.00
Net Margins: -70.79%
Pretax Margin: -70.79%
Return on Equity: -76.19%
Return on Assets: -43.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.49
Quick Ratio: 4.44

Sales & Book Value

Annual Sales: $40.58 million
Price / Sales: 9.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.11 per share
Price / Book: 2.13

Miscellaneous

Outstanding Shares: 19,610,000
Free Float: 18,260,000
Market Cap: $379.65 million
Optionable: Optionable
Beta: 0.93

Social Links

Key Executives

Mr. Ronald H. W. Cooper (Age 59)
CEO, Pres & Director
Comp: $1.1M

Mr. Simon Nicolas Reade Harford (Age 61)
CFO & Treasurer
Comp: $687.78k

Ms. Martha J. Carter (Age 70)
Chief Regulatory Officer
Comp: $710.69k

Dr. Per-Goran Gillberg Ph.D.
Co-Founder & VP of Devel.

Dr. Jan P. Mattsson Ph.D. (Age 58)
Chief Scientific Officer, MD (Sweden) & Co-Founder

Ms. Joan Connolly
Chief Technology Officer

Mr. Jason G. Duncan (Age 48)
Chief Legal Officer, Gen. Counsel & Sec.

Ms. Michelle Graham (Age 55)
Chief HR Officer

Dr. Kristina Torfgard
VP & Global Project Head

Ms. Pamela Stephenson M.P.H. (Age 54)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALBO shares.
View ALBO analyst ratings or view top-rated stocks.
What is Albireo Pharma's stock price forecast for 2022?: 4 Wall Street research analysts have issued 1 year price targets for Albireo Pharma's shares. Their ALBO share price forecasts range from $43.00 to $61.00. On average, they anticipate the company's share price to reach $53.25 in the next year. This suggests a possible upside of 175.1% from the stock's current price.
View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts.
How have ALBO shares performed in 2022?: Albireo Pharma's stock was trading at $23.29 at the start of the year. Since then, ALBO shares have decreased by 16.9% and is now trading at $19.36.
View the best growth stocks for 2022 here.
When is Albireo Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ALBO earnings forecast.
How were Albireo Pharma's earnings last quarter?: Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Monday, August, 15th. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing the consensus estimate of ($1.58) by $0.46. The biopharmaceutical company earned $8.21 million during the quarter, compared to analysts' expectations of $9.42 million. Albireo Pharma had a negative trailing twelve-month return on equity of 76.19% and a negative net margin of 70.79%. During the same quarter last year, the business posted ($1.90) earnings per share.

What other stocks do shareholders of Albireo Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).
What is Albireo Pharma's stock symbol?: Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How do I buy shares of Albireo Pharma?: Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Albireo Pharma's stock price today?: One share of ALBO stock can currently be purchased for approximately $19.36.
How much money does Albireo Pharma make?: Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $379.65 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.
How many employees does Albireo Pharma have?: The company employs 130 workers across the globe.
How can I contact Albireo Pharma?: Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Albireo Pharma - ALBO Stock Forecast, Price & News

Albireo Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability